Oxford Gene Technology (OGT), A Sysmex Group Company, is excited to announce the launch of its SureSeq CLL + CNV Panel — the company’s latest high-quality, next-generation sequencing (NGS) offering ...
Prevalence of familial malignancy in a prospectively screened cohort of patients with leukemia. Background: Recurring chromosomal aberrations are detectable in ∼70% of patients (pts) with CLL using ...
Test detects genetic abnormalities to aid in the prediction of chronic lymphocytic leukemia patient survival. Abbott received 510k clearance for an in vitro diagnostic test to aid in determining the ...
The application of in situ hybridization (ISH) has advanced from generalized, short-term isotopic methods, to long-term, highly specialized, multicolor Fluorescent-ISH probe assays (FISH).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results